Myopia Research Today is a free monthly online journal that collates and summarizes the latest research about Myopia, including details on treatment, prevention, causes, correction.

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

Chan WM, Lai TY, Liu DT, Lam DS

Hong Kong Eye Hospital, Department of Ophthalmology & Visual Sciences, Chinese University of Hong Kong, Hong Kong, China. cwm6373@netvigator.com

PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM). DESIGN: Prospective, consecutive, nonrandomized, interventional case series. PARTICIPANTS: Twenty-two eyes of 22 patients with CNV secondary to PM. METHODS: Consecutive patients with subfoveal or juxtafoveal CNV secondary to PM were recruited prospectively to receive an initial course of 3 monthly intravitreal injections of bevacizumab. Three additional monthly injections were performed in eyes with persistent CNV leakage after 3 months. Patients were followed up for 6 months, and the best-corrected visual acuity (BCVA), changes in fluorescein angiography, and optical coherence tomography (OCT) results were assessed. MAIN OUTCOME MEASURES: Changes in BCVA, angiographic closure, and OCT central foveal thickness (CFT) at the 6-month follow-up. RESULTS: The mean+/-standard deviation (SD) spherical equivalent refractive error of the 22 eyes was -10.3+/-3.7 D (range, -6.0D to -18.0D). All patients completed follow-up at 6 months. Twenty (90.9%) eyes had angiographic closure after 3 monthly injections of intravitreal bevacizumab, and 2 (9.1%) eyes required further treatment up to 6 months. The mean+/-SD logarithm of the minimum angle of resolution (logMAR) BCVA at baseline was 0.60+/-0.18 (Snellen equivalent, 20/80). At 1 and 6 months, the mean+/-SD logMAR BCVA improved significantly to 0.43 (Snellen equivalent, 20/53; P = 0.003) and 0.35 (Snellen equivalent, 20/45; P<0.001), respectively. The mean lines of improvements at 1 and 6 month compared with baseline were 1.7 and 2.6 lines, respectively. Fifteen (68.2%) eyes had an improvement of 2 or more lines at 6 months. The OCT results also showed significant reduction in CFT after treatment. No ocular or systemic complications were noted after intravitreal injections. CONCLUSIONS: The 6-month outcomes suggest intravitreal bevacizumab to be a promising treatment method for CNV secondary to PM, resulting in both visual and anatomic improvements. Treatment resulted in complete absence of angiographic leakage in 90.9% of eyes at 3 months. Further studies to evaluate the safety, efficacy, and optimal treatment regimen are justified.

Published 6 December 2007 in Ophthalmology, 114(12): 2190-6.
Full-text of this article is available online (may require subscription).

© 2004-2008 Myopia Research Today. All Rights Reserved.